Northwire Canada EditionFriday, July 10, 2026
Sign inSubscribe
Northwire
⌕
AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0% OGN 3.45 +2.1% MSA 6.67 +3.7% SGZ 0.040 −11.1% GRSL 0.310 −3.1% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0% OGN 3.45 +2.1% MSA 6.67 +3.7% SGZ 0.040 −11.1% GRSL 0.310 −3.1%
Financings Routine +

VVT Med Expands into the Dominican Republic, Appointing Antilles Medical as Exclusive Distributor

Early-stage venous disease device maker scales global distribution while navigating regulatory delays and dilutive capital raises.

By The Northwire Desk — AI Analysis Jun 11, 2026 · 08:30 VVTM · 0.265 VVT Med Inc.
Executive Summary
  • VVT Med announced a trial distribution agreement with Antilles Medical to exclusively distribute its ScleroSafe™ system in the Dominican Republic, establishing a structured pathway to a five-year exclusive partnership.
  • The company confirmed the closing of the first tranche of a non-brokered private placement, raising $1,065,663.50 from the issuance of 4,262,654 units at $0.25 per unit.
  • Each unit comprises one common share and one-half of a common share purchase warrant, exercisable at $0.375 per share for 24 months.
  • A second tranche of identical terms is planned to close on or about July 20, 2026, subject to TSX Venture Exchange approval and a four-month hold period.
  • Proceeds will fund expanded U.S. and global commercialization, product manufacturing, working capital, and general corporate purposes.
Material Impact
  • The distribution expansion is an incremental step in the company's geographic rollout, following recent entries into Italy, India, North Macedonia, and the U.S.
  • The financing provides necessary liquidity but continues a pattern of dilutive capital raises at declining share prices ($0.31 in Nov 2025, $0.25 in Apr/Jun 2026).
  • The Management Cease Trade Order (MCTO) remains in effect until the June 29, 2026 filing deadline, restricting insider trading and new insider issuances.
  • The news does not alter the fundamental trajectory: the company is burning cash, generating minimal revenue, and relying on distributor commitments rather than direct end-user sales.
VVTM · Price
Company Overview
  • VVT Med Inc. develops and commercializes the ScleroSafe™ system, a non-thermal, non-tumescent (NT-NT) medical device for treating venous disease.
  • The technology enables controlled sclerosant delivery with simultaneous blood aspiration, aiming to improve physician efficiency and patient comfort compared to traditional thermal or tumescent methods.
  • The company is pursuing a global commercialization strategy through exclusive distribution agreements, having secured partnerships in India, Italy, North Macedonia, the U.S., and now the Dominican Republic.
  • The business is in the early commercialization phase, relying on distributor networks rather than a direct sales force.
Read the original news release →

More from VVT Med Inc.

Jun 26, 2026 · 06:45

VVT Med Expands European Commercial Footprint Through Exclusive Distribution Agreement in Greece

Other Jun 12, 2026 · 17:00

Bi-weekly regulatory update on delayed filings and ongoing MCTO restricts insider trading while commercial expansion continues.

Regulatory May 29, 2026 · 17:32

VVT Med’s Italian Breakthrough Overshadowed as Cease Trade Order Drags Shares to Multi‑Year Lows

Regulatory May 26, 2026 · 08:00

Operational Milestone Achieved Amidst Regulatory Overhang

Production / Operations May 15, 2026 · 17:31

Governance Risks Persist Despite Commercial Traction

Regulatory May 01, 2026 · 19:44

VVT Med Cease Trade Order Halts Financing Flexibility Amidst Commercial Momentum

Regulatory